One-Year Results of a Phase I/II Randomized, Double-Masked, Placebo-Controlled Study of Processed Amniotic Fluid Drops After PRK

被引:2
|
作者
Kirschenbaum, Malka Davina [1 ]
Hu, Katherine S. [1 ]
Ip, Colin S. [1 ]
Lin, Amy [1 ]
Pierce, Jan [2 ]
Holubkov, Richard [3 ]
Jensen, Hailey [3 ]
Mifflin, Mark D. [1 ]
机构
[1] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA
[2] Univ Utah, Cell Therapy & Regenerat Med, Salt Lake City, UT USA
[3] Univ Utah, Dept Pediat, Salt Lake City, UT USA
关键词
amniotic fluid; PRK; refractive; laser; MEMBRANE TRANSPLANTATION; SUSPENSION; OUTCOMES; EYE;
D O I
10.1097/ICO.0000000000003474
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose:The aim of this study was to evaluate the 1-year outcomes of using processed amniotic fluid (pAF) postoperatively after photorefractive keratectomy (PRK).Methods:Sixty-one participants were randomized to receive either placebo or pAF drops. The drops were instilled 4 times daily for 1 week after PRK along with routine postoperative medications. The primary outcome measures included uncorrected visual acuity, topographic corneal irregularity measurement, and surface staining over 1 year.Results:A statistically significant difference in uncorrected distance visual acuity between the placebo and treatment groups was seen at 1 month post-PRK, with a visual advantage evident in the pAF group. A suggestive difference in corneal irregularity measurement was also seen between the placebo and treatment groups at 1 month postsurgery, with less irregularity noted in the pAF group. No differences in uncorrected distance visual acuity or corneal irregularity measurement were found at 3, 6, and 12 months. There was also no significant difference in corneal staining scores between the 2 groups at any of the measured time points.Conclusions:This 1-year study evaluating the safety and efficacy of pAF as an additional postoperative topical medication after PRK demonstrated that pAF offered a mild visual advantage at 1 month post-PRK. There were no late adverse events, and the intervention proved safe at 1 year.
引用
收藏
页码:955 / 960
页数:6
相关论文
共 50 条
  • [41] A Multicenter, Randomized, Double-Masked, Dose-Ranging, Placebo-Controlled Phase 2 Study to Assess Sirolimus in the Treatment of Patients With Diabetic Macular Edema (DIAMOND Study)
    Naor, J.
    Dugel, P. U.
    Weber, D. A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [42] Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
    Kavanaugh, Arthur
    van der Heijde, Desiree
    McInnes, Iain B.
    Mease, Philip
    Krueger, Gerald G.
    Gladman, Dafna D.
    Gomez-Reino, Juan
    Papp, Kim
    Baratelle, Anna
    Xu, Weichun
    Mudivarthy, Surekha
    Mack, Michael
    Rahman, Mahboob U.
    Xu, Zhenhua
    Zrubek, Julie
    Beutler, Anna
    ARTHRITIS AND RHEUMATISM, 2012, 64 (08): : 2504 - 2517
  • [43] A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease
    Schmidl, Doreen
    Szalai, Laszlo
    Kiss, Orsolya G.
    Schmetterer, Leopold
    Garhofer, Gerhard
    ADVANCES IN THERAPY, 2021, 38 (04) : 1975 - 1986
  • [44] A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease
    Doreen Schmidl
    László Szalai
    Orsolya G. Kiss
    Leopold Schmetterer
    Gerhard Garhöfer
    Advances in Therapy, 2021, 38 : 1975 - 1986
  • [45] A Phase 2 randomized, double-masked, placebo-controlled study of novel narrow spectrum kinase inhibitor TOP1630 for the treatment of dry eye syndrome
    Taylor, Mike
    Duggal, Ajay
    Walshe, Claire
    Fyfe, Matthew
    Rowley, Adele
    Webber, Steve
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [46] Phase I/II, Double-Masked, Randomized, Vehicle-Controlled Study of H-1337 Ophthalmic Solution for Glaucoma and Ocular Hypertension
    Hartman, Paul J.
    Cooke, David L.
    Hsu, Henry H.
    Stewart, Jeanette
    Sumi, Kengo
    Yoshida, Yoko
    Hidaka, Hiroyoshi
    Novack, Gary D.
    OPHTHALMOLOGY GLAUCOMA, 2023, 6 (02): : 198 - 205
  • [47] Effect of short-term vitamin D supplementation after nonsurgical periodontal treatment: A randomized, double-masked, placebo-controlled clinical trial
    Gao, Weimin
    Tang, Huilin
    Wang, Danyang
    Zhou, Xuan
    Song, Yiqing
    Wang, Zuomin
    JOURNAL OF PERIODONTAL RESEARCH, 2020, 55 (03) : 354 - 362
  • [48] The Use of Etoricoxib and Celecoxib for Pain Prevention After Periodontal Surgery: A Double-Masked, Parallel-Group, Placebo-Controlled, Randomized Clinical Trial
    Steffens, Joao Paulo
    Santos, Fabio Andre
    Pilatti, Gibson Luiz
    JOURNAL OF PERIODONTOLOGY, 2011, 82 (09) : 1238 - 1244
  • [49] Safety of efalizumab in patients with psoriatic arthritis: Results of a phase II, randomized, double-blind, placebo-controlled study
    Papp, K
    Mease, P
    Garovoy, M
    Zhang, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [50] ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy
    Nguyen, Quan Dong
    Ehlers, Justis P.
    Boyer, David S.
    Jin, Xidong
    Giani, Andrea
    Ehrlich, Michael S.
    EYE, 2024, 38 (10) : 1861 - 1869